Ikena Oncology, Inc.

NasdaqGM:IKNA Stok Raporu

Piyasa değeri: US$82.5m

Ikena Oncology Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mark Manfredi

İcra Kurulu Başkanı

US$1.2m

Toplam tazminat

CEO maaş yüzdesi45.9%
CEO görev süresi6.9yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi1.1yrs
Yönetim Kurulu ortalama görev süresi4yrs

Son yönetim güncellemeleri

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Jun 01
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Jun 01
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Aug 15
Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

May 20
Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

Apr 29
Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Jan 06
We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Aug 06
Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Mar 23
Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 21
Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

Feb 19
Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Nov 02
We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

Jul 13
Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

CEO Tazminat Analizi

Mark Manfredi'un ücretlendirmesi Ikena Oncology'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$67m

Mar 31 2024n/an/a

-US$70m

Dec 31 2023US$1mUS$569k

-US$68m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$546k

-US$69m

Sep 30 2022n/an/a

-US$52m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$5mUS$530k

-US$34m

Sep 30 2021n/an/a

-US$63m

Jun 30 2021n/an/a

-US$55m

Mar 31 2021n/an/a

-US$47m

Dec 31 2020US$606kUS$410k

-US$44m

Tazminat ve Piyasa: Mark 'nin toplam tazminatı ($USD 1.24M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 654.40K ).

Tazminat ve Kazançlar: Mark 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Mark Manfredi (53 yo)

6.9yrs

Görev süresi

US$1,240,640

Tazminat

Dr. Mark Manfredi, Ph D., serves as Member of Scientific Advisory Board of Bantam Pharmaceutical, LLC. He has been President, Chief Executive Officer and Director of Ikena Oncology, Inc. since December 201...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Mark Manfredi
President6.9yrsUS$1.24mVeri yok
Jotin Marango
CFO & Head of Corporate Development2.6yrsUS$782.32k0%
$ 0
Rebecca Cohen
Vice President of Investor Relationsless than a yearVeri yokVeri yok
Jeffrey Ecsedy
Chief Development Officer3yrsVeri yokVeri yok
Bob Lally
Senior Vice President of Finance & Operationsno dataVeri yokVeri yok
David Damphousse
Senior Vice President of Clinical Development Operations1.1yrsVeri yokVeri yok
Caroline Germa
Chief Medical Officerless than a yearVeri yokVeri yok
Valdas Jurkauskas
Senior Vice President of Technical Operationsless than a yearVeri yokVeri yok

1.1yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim: IKNA 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Mark Manfredi
President6.9yrsUS$1.24mVeri yok
Jean-Francois Formela
Independent Director8.7yrsUS$130.36k0%
$ 0
George Demetri
Chair of Scientific Advisory Board4yrsVeri yokVeri yok
Otello Stampacchia
Independent Director3.9yrsUS$128.25k0%
$ 0
Neal Rosen
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Kevan Shokat
Member of Scientific Advisory Board4yrsVeri yokVeri yok
Owen Hughes
Chairman of the Board1.8yrsUS$167.86k0%
$ 0
David Bonita
Independent Director8.7yrsUS$131.86k0%
$ 0
Iain Dukes
Independent Director8yrsUS$126.97k0%
$ 0
Richard Wooster
Independent Director2.8yrsUS$117.86k0%
$ 0
Josep Tabernero Caturla
Member of Scientific Advisory Board4yrsVeri yokVeri yok
Maria Koehler
Independent Director3.6yrsUS$117.86k0%
$ 0

4.0yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IKNA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).